Sarepta Price Target Slashed To $0 At H.C. Wainwright As Stock Plunge Continues
Shares of Sarepta dropped as much as 11% in premarket trading and remain down about 6% after the cash open this morning.
The decline follows H.C. Wainwright’s reiteration of its Sell rating and a drastic cut in its price target—from $10 to $0—after the FDA requested Sarepta voluntarily withdraw its ELEVIDYS gene therapy from the market. S…
Sarepta Price Target Slashed To $0 At H.C. Wainwright As Stock Plunge Continues
July 21, 2025